Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Socié, Gérard  [Clear All Filters]
2020
Maffini, E., Labopin, M., Blaise, D., Ciceri, F., Gulbas, Z., Deconinck, E., Leblond, V., Chevallier, P., Socié, G., Araujo, M.Colorado, et al. (2020). CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European.Am J Hematol.
Peric, Z., Labopin, M., Peczynski, C., Polge, E., Cornelissen, J., Carpenter, B., Potter, M., Malladi, R., Byrne, J., Schouten, H., et al. (2020). Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.Bone Marrow Transplant.
Payen, M., Nicolis, I., Robin, M., Michonneau, D., Delannoye, J., Mayeur, C., Kapel, N., Berçot, B., Butel, M.-J., Le Goff, J., et al. (2020). Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity.Blood Adv4, 1824-1832.
Bazarbachi, A., Labopin, M., Angelucci, E., Gulbas, Z., Ozdoğu, H., Arat, M., de Rosa, L., Pastano, R., Pioltelli, P., Montserrat, R., et al. (2020). Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party.Biol Blood Marrow Transplant.
Penack, O., Marchetti, M., Ruutu, T., Aljurf, M., Bacigalupo, A., Bonifazi, F., Ciceri, F., Cornelissen, J., Malladi, R., Duarte, R.F., et al. (2020). Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.Lancet Haematol7, e157-e167.
Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E.M., Zuckerman, T., Mahuzier, B., et al. (2020). Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.N Engl J Med.
2019
Radujkovic, A., Dietrich, S., Blok, H.-J., Nagler, A., Ayuk, F., Finke, J., Tischer, J., Mayer, J., Koc, Y., Sorà, F., et al. (2019). Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party.Biol Blood Marrow Transplant.
Cheng, G.-S., Bondeelle, L., Gooley, T., He, Q., Jamani, K., Krakow, E.F., Flowers, M.E.D., de Latour, R.Peffault, Michonneau, D., Socié, G., et al. (2019). Azithromycin use and increased cancer risk among patients with bronchiolitis obliterans after hematopoietic cell transplantation.Biol Blood Marrow Transplant.
Fayard, A., Daguenet, E., Blaise, D., Chevallier, P., Labussière, H., Berceanu, A., Yakoub-Agha, I., Socié, G., Charbonnier, A., Suarez, F., et al. (2019). Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell.Bone Marrow Transplant.
Hamilton, B.K., Liu, Y., Hemmer, M.T., Majhail, N., Ringdén, O., Kim, D., Costa, L., Stuart, R., Alousi, A., Pidala, J.A., et al. (2019). Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.
de Latour, R.Peffault, Chevret, S., Ruggeri, A.Lisa, Suarez, F., Souchet, L., Michonneau, D., de Fontbrune, F.Sicre, Coman, T., Dhedin, N., Rubio, M.Thérèse, et al. (2019). Romiplostim in Patients undergoing Hematopoietic Stem Cell Transplantation: Results of a Phase I/II multicenter Trial.Blood.
Gorin, N.-C., Labopin, M., Blaise, D., de Groot, M., Socié, G., Bourhis, J.Henri, Ciceri, F., Polge, E., Nagler, A., and Mohty, M. (2019). Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood a.Cancer.
Beelen, D.Wilhelm, Trenschel, R., Stelljes, M., Groth, C., Masszi, T., Reményi, P., Wagner-Drouet, E.-M., Hauptrock, B., Dreger, P., Luft, T., et al. (2019). Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 .Lancet Haematol.
2018
Chhabra, S., Liu, Y., Hemmer, M.T., Costa, L., Pidala, J.A., Couriel, D.R., Alousi, A.M., Majhail, N.S., Stuart, R.K., Kim, D., et al. (2018). Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation.Biol Blood Marrow Transplant.
Tichelli, A., Beohou, E., Labopin, M., Socié, G., Rovó, A., Badoglio, M., van Biezen, A., Bader, P., Duarte, R.F., Basak, G., et al. (2018). Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients.Jama Oncol.
Gilleece, M.H., Labopin, M., Yakoub-Agha, I., Volin, L., Socié, G., Ljungman, P., Huynh, A., Deconinck, E., Wu, D., Bourhis, J.Henri, et al. (2018). Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu.Am J Hematol.
Frick, M., Chan, W., Arends, C.Maximilian, Hablesreiter, R., Halik, A., Heuser, M., Michonneau, D., Blau, O., Hoyer, K., Christen, F., et al. (2018). Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.J Clin OncolJCO2018792184.
Belkacemi, Y., Labopin, M., Giebel, S., Gorin, N.Claude, Loganadane, G., Miszczyk, L., Michallet, M., Socié, G., Schaap, N.Pm, Cornelissen, J.J., et al. (2018). Single Dose Daily Fractionated Is Not Inferior To Twice A Day Fractionated Total Body Irradiation Prior To Allogeneic Stem Cell Transplantation For Acute Leukemia: A Useful Practice Simplification Resulting From The Sarasin Study.Int J Radiat Oncol Biol Phys.
Canaani, J., Beohou, E., Labopin, M., Ghavamzadeh, A., Beelen, D., Hamladji, R.-M., Niederwieser, D., Volin, L., Markiewicz, M., Arnold, R., et al. (2018). Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukemia. An ALWP/EBMT analysis.J Intern Med.
Ruggiu, M., Bedossa, P., Rautou, P.Emmanuel, Bertheau, P., Plessier, A., de Latour, R.Peffault, Robin, M., de Fontbrune, F.Sicre, Pagliuca, S., Villate, A., et al. (2018). Utility and safety of liver biopsy in patients with undetermined liver blood test anomalies after allogeneic hematopoietic stem cell transplantation, a monocentric retrospective cohort study.Biol Blood Marrow Transplant.

Pages